Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bennouna

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|October 27, 2011
Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trialB Melichar, E Casado, J Bridgewater, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2022
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)D Basile, C Broudin, J F Emile, et al.
Respiratory Medicine and Research|June 22, 2020
Proposals for managing patients with thoracic malignancies during COVID-19 pandemicN Girard, L Greillier, G Zalcman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1G Robinet, P Thomas, J L Breton, et al.
Cancer Immunology, Immunotherapy : CII|January 23, 2023
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50E Pons-Tostivint, P Hulo, V Guardiolle, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2023
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50E Pons-Tostivint, P Hulo, V Guardiolle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2015
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)J Vansteenkiste, F Barlesi, C F Waller, et al.
British Journal of Cancer|January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialE Samalin, O Bouché, S Thézenas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canalP A Ott, S A Piha-Paul, P Munster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|October 27, 2011
Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trialB Melichar, E Casado, J Bridgewater, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2022
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)D Basile, C Broudin, J F Emile, et al.
Respiratory Medicine and Research|June 22, 2020
Proposals for managing patients with thoracic malignancies during COVID-19 pandemicN Girard, L Greillier, G Zalcman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1G Robinet, P Thomas, J L Breton, et al.
Cancer Immunology, Immunotherapy : CII|January 23, 2023
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50E Pons-Tostivint, P Hulo, V Guardiolle, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2023
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50E Pons-Tostivint, P Hulo, V Guardiolle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2015
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)J Vansteenkiste, F Barlesi, C F Waller, et al.
British Journal of Cancer|January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialE Samalin, O Bouché, S Thézenas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canalP A Ott, S A Piha-Paul, P Munster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Pageof 6